Skye Bioscience, Inc.
About Skye Bioscience, Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$55.9M
- Total assets
- $28.3M
- Market cap
- $25.8M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $58.2M
- Operating income
- -$58.2M
- Income tax
- $5.4K
- Net income
- -$55.9M
- EPS (basic)
- $-1.41
- EPS (diluted)
- $-1.41
Balance sheet
- Total assets
- $28.3M
- Current assets
- $27.1M
- Total liabilities
- $8.3M
- Current liabilities
- $8.2M
- Shareholders’ equity
- $20.0M
Cash flow
- Operating cash flow
- -$43.1M
- Investing cash flow
- -$19.5M
- Financing cash flow
- $29.6K
- Net cash flow
- -$62.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $25.8M
- EPS (diluted)
- $-1.41
- Shares outstanding
- 33.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 24, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $55.9M.
- Trading 84% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Skye Bioscience, Inc..
Write a review
News about Skye Bioscience, Inc.
News & sentiment via Polygon.io
